1. Home
  2. VMD vs PRME Comparison

VMD vs PRME Comparison

Compare VMD & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viemed Healthcare Inc.

VMD

Viemed Healthcare Inc.

HOLD

Current Price

$11.75

Market Cap

465.4M

Sector

N/A

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$2.94

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VMD
PRME
Founded
2006
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
465.4M
536.4M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
VMD
PRME
Price
$11.75
$2.94
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$7.56
AVG Volume (30 Days)
335.1K
4.3M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
32.14
18.18
EPS
0.06
N/A
Revenue
$270,280,000.00
$4,632,000.00
Revenue This Year
$17.88
$7.06
Revenue Next Year
$14.98
$47.01
P/E Ratio
$194.50
N/A
Revenue Growth
20.52
55.28
52 Week Low
$5.93
$2.67
52 Week High
$12.61
$6.94

Technical Indicators

Market Signals
Indicator
VMD
PRME
Relative Strength Index (RSI) 56.47 38.81
Support Level $11.71 $2.68
Resistance Level $12.61 $3.68
Average True Range (ATR) 0.35 0.27
MACD -0.11 -0.11
Stochastic Oscillator 28.18 4.33

Price Performance

Historical Comparison
VMD
PRME

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: